CP-035 EVALUATION OF THE THERAPEUTIC STRATEGIES USED FOR THE TREATMENT OF THE HEPATITIS C VIRUS GENOTYPE 3 INFECTION

Del Río Valencia J.C., Asensi Díez R., Madera Pajín R., Muñoz Castillo I.
SERVICIO DE FARMACIA HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA

Hospital Regional Universitario Carlos Haya de Málaga

22nd Congress of the EAHP
Hospital pharmacists - catalysts for change
22-24 March 2017, Cannes, France
Register before 31st January 2017 for the discount rate

BACKGROUND

Hepatitis C is a serious health problem with high prevalence rates, being the leading cause of liver transplantation. The development of well tolerated and highly effective direct active antivirals (DAAs) for hepatitis C virus (HCV) dramatically changed the therapeutic landscape.

PURPOSE

To assess the effectiveness of sosbuvir/daclatasvir (SOF+DCV) compared to sofosbuvir/ledipasvir (SOF/LDV) used for the treatment of the hepatitis C virus genotype-3 infection.

MATERIAL AND METHODS

Retrospective and observational study between April 2015 and January 2016.

Inclusion criteria: → Patients with HCV genotype-3 infection treated with SOF/LDV±Ribavirin (RBV) or with SOF+DCV during study period.

Outcomes collected: → Demographics: age and sex.

→ Clinical data: . basal viral load (VL) .METAVIR score: F0-F4. .Liver transplant. .HIV co-infection

.SVR at week 12 (SVR12), defined as HCV RNA titres lower than 15 IU/mL. . Previous treatments for HCV.

→ Data were collected from the medical records of patients.

RESULTS







Treatment with SOF/LDV±RBV: 20 patients were included (65% male) with mean age of 53.05±9.05 years. Patients were treated 12 weeks. According to METAVIR score: F4 (cirrhosis) (45%), F3 (35%), F2 (15%), F1 (5%). 10% of Patients were HIV-coinfected, 15% had a liver transplant and 30% were pretreated with RBV/peginterferon. 45% of patients had an initial VL>800.000UI/ml.

20 patients (85% male) were included with mean age of 53.05±9.05 years. Patients were treated 12 weeks. According to METAVIR score: F4 (cirrhosis) 50%, F3 (20%), F2 (20%), F1 (10%).HIV-coinfected patients 45%, pretreated with RBV/peginterferon 25% and 30% had basal VL>800,000UI/ml.

CONCLUSION

Treatment with SOF+DCV seems to be more effective in our study. This matches the upper SVR12 rate achieved in ALLY-3 for SOF+DCV compared with results obtained in ELECTRON-2 for SOF/LDV in genotype 3, although the sample size and different baseline characteristics of the patients could be influencing these results..

ACKNOWLEDGEMENTS

No conflict of interest

juancarcardelrio@telefónica.net

J05- ANTIVIRALS FOR SYSTEMIC USE